Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioHarvest Sciences ( (BHST) ) is now available.
On April 29, 2026, BioHarvest Sciences announced a strategic leadership transition aimed at sharpening execution of its dual focus on direct-to-consumer and CDMO operations. Co-founder and Executive Chairman Dr. Zaki Rakib assumed the role of Chief Executive Officer, consolidating leadership of R&D, manufacturing, and operations in the CDMO division under a unified structure.
Former CEO Ilan Sobel, who led the company from a pre-revenue stage to about $35 million in fiscal 2025 revenue and a Nasdaq listing, transitioned from his executive post to join the board of directors, where he will concentrate on advancing the direct-to-consumer business. The board emphasized Dr. Rakib’s deep institutional knowledge and prior success building high-growth companies as key to driving the next phase of BioHarvest’s growth trajectory.
The most recent analyst rating on (BHST) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by ongoing cash burn and lack of profitability, alongside weak technical trend signals (trading below key moving averages with negative MACD). Offsetting these risks, the latest earnings call pointed to strong revenue growth, improving margins/operating leverage, a much stronger cash position, and constructive 2026 targets (D2C profitability and higher CDMO revenue), which provide a meaningful—but not yet proven—upside catalyst.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a Canadian biotechnology company focused on leveraging a proprietary technology platform across two main businesses: a direct-to-consumer channel and a Contract Development and Manufacturing Organization (CDMO) division. The company has evolved into a fully operational, Nasdaq-listed growth platform, generating approximately $35 million in revenue in fiscal 2025 as it scales its commercial operations.
Average Trading Volume: 27,119
Technical Sentiment Signal: Buy
Current Market Cap: $89.99M
Find detailed analytics on BHST stock on TipRanks’ Stock Analysis page.